Xenetic Biosciences, Inc. Ownership
$2.47
1.98%
Nasdaq, Sep 24, 04:00 pm EDT.
Closed.
Xenetic Biosciences, Inc. Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
CLS Therapeutics, Ltd.
|
147.500k | 6.30% | — | Oct 15 2025 |
| 2 |
Renaissance Technologies LLC
|
137.440k | 5.87% | -41.069k | Mar 31 2026 |
| 3 |
Parslow (James F)
|
100.000k | 4.27% | +100.000k | Apr 21 2026 |
| 4 |
Genkin (Dmitry Dmitrievich)
|
68.464k | 2.93% | — | Oct 15 2025 |
| 5 |
Geode Capital Management, L.L.C.
|
21.441k | 0.92% | +7.860k | Mar 31 2026 |
|
1
CLS Therapeutics, Ltd.
|
6.30%
147.500k
|
|
2
Renaissance Technologies LLC
|
5.87%
137.440k
|
|
3
Parslow (James F)
|
4.27%
100.000k
|
|
4
Genkin (Dmitry Dmitrievich)
|
2.93%
68.464k
|
|
5
Geode Capital Management, L.L.C.
|
0.92%
21.441k
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 20.29% of Xenetic Biosciences, Inc., with CLS Therapeutics, Ltd. the biggest at 6.30%, followed by Renaissance Technologies LLC (5.87%) and Parslow (James F) (4.27%). |
Xenetic Biosciences, Inc. Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Xenetic Biosciences, Inc. has held steady at around 0.9% of the float over the past 12 months. Short sellers' positioning has barely changed in this period. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
